Olympus Corp
TSE:7733

Watchlist Manager
Olympus Corp Logo
Olympus Corp
TSE:7733
Watchlist
Price: 2 360.5 JPY -0.63% Market Closed
Market Cap: 2.8T JPY
Have any thoughts about
Olympus Corp?
Write Note

Olympus Corp
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Olympus Corp
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
Olympus Corp
TSE:7733
Other Equity
ÂĄ122.6B
CAGR 3-Years
233%
CAGR 5-Years
N/A
CAGR 10-Years
46%
Terumo Corp
TSE:4543
Other Equity
ÂĄ235.9B
CAGR 3-Years
240%
CAGR 5-Years
N/A
CAGR 10-Years
15%
Sysmex Corp
TSE:6869
Other Equity
ÂĄ33.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
13%
Nihon Kohden Corp
TSE:6849
Other Equity
ÂĄ7.8B
CAGR 3-Years
45%
CAGR 5-Years
69%
CAGR 10-Years
17%
JEOL Ltd
TSE:6951
Other Equity
ÂĄ3.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Fukuda Denshi Co Ltd
TSE:6960
Other Equity
ÂĄ1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Olympus Corp
Glance View

Market Cap
2.7T JPY
Industry
Health Care

Olympus Corporation, originating from the heart of Japan in 1919, has evolved into a global powerhouse, particularly revered for its contributions to the field of optics and imaging. Initially carving its reputation through crafting precision microscope lenses, Olympus seamlessly expanded its capabilities into the realms of endoscopy and digital imaging. This strategic pivot not only defined its legacy but firmly anchored its presence in the medical world, where it became a leader in endoscopic technology. The company adeptly leveraged its expertise to revolutionize medical diagnostics and treatment, helping medical professionals see and diagnose better—enhancing both physician dexterity and patient outcomes. Revenue for Olympus is predominantly driven by its Medical Business sector, which constitutes a significant portion of its overall profits, underscoring its transformation from a diversified manufacturer to a specialized player in healthcare technology. They are deeply committed to R&D, funneling substantial resources to innovate and bolster their portfolio in medical devices, particularly in fields like therapeutic interventions. While imaging products for consumers have historically been a notable segment, the shift toward medical technology aligns with broader market demands and ensures sustainable growth. This focus demonstrates Olympus's intent to maximize its competitive advantages, allowing it to remain at the forefront of its niche industries and effectively respond to global healthcare challenges.

Intrinsic Value
2 766.08 JPY
Undervaluation 15%
Intrinsic Value
Price

See Also

What is Olympus Corp's Other Equity?
Other Equity
122.6B JPY

Based on the financial report for Sep 30, 2024, Olympus Corp's Other Equity amounts to 122.6B JPY.

What is Olympus Corp's Other Equity growth rate?
Other Equity CAGR 10Y
46%

Over the last year, the Other Equity growth was -10%. The average annual Other Equity growth rates for Olympus Corp have been 233% over the past three years , and 46% over the past ten years .

Back to Top